NCT01555580UnknownEarly Phase 1
A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Symptomatic Autoimmune Generalized Myasthenia Gravis
Muscular Dystrophy Association1 site in 1 country12 target enrollmentStarted: April 2012Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Early Phase 1
- Sponsor
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Safety of GM-CSF in patients with myasthenia gravis
Study Overview
Brief Summary
The purpose of this study is to determine whether the drug Leukine (GM-CFS) is safe and tolerated by patients with autoimmune myasthenia gravis (MG).
Detailed Description
Twelve patients aged 18-80 with symptomatic generalized autoimmune MG that are not being treated with medication that suppresses their immune system, other than prednisone, will enter the study at UIC over a two year period. The study will involve a screening visit and visits at baseline and at days 5, 15, 30, 45, 60, 90, and 120. The study drug, Leukine (GM-CFS), is given by injection. Subjects will give themselves one dose of GM-CSF every day for 10 days. Study visits will include muscle testing, immunologic studies and quality-of-life studies.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Must be between 18 and 80 years of age
- •Established diagnosis of myasthenia based on: the presence of fatigable weakness of ocular, oropharyngeal, and/or limb muscles AND the presence of abnormal acetylcholine receptor binding antibodies ≥ 0.4 nmol/l.
- •Patients of childbearing potential must agree to use a medically acceptable form of contraception defined by consistent use of oral contraceptive medications or history of tubal ligation or men who are in sexual relationship with such women during and for at least 8 weeks following completion of the study.
- •Patient or designee must have the ability to self-inject investigational product
- •If thymectomized, the procedure must have been performed at least one year prior to screening.
- •Dose of current anticholinesterase drugs must be constant for 2 weeks prior to screening.
- •If taking prednisone, dose must be stable for ≥4 weeks prior to screening.
- •Exclusion criteria:
- •exclusively ocular MG (MGFA Class I)
- •severe respiratory and/ or swallowing muscle weakness (MGFA Class Vb or V)
- •presence of thymoma
- •Must not have received plasm exchange or IVIG within 4 weeks of screening
- •Must not have received immuno-modulating agents within the 4 weeks of screening, including Azathioprine (Imuran), Cyclosporine (Sandimmune, Neoral), Mycophenolate mofetil (CellCept), GM-CSF (Filgrastim; Neupogen; pegfilgrastim, sargramostim), or any other chronic immunosuppressive agent
- •History of tuberculosis or evidence of latent tuberculosis (positive PPD skin test or a chest X-ray with evidence of tuberculosis)
- •vital capacity of less than 1.2 liters or on supplemental oxygen therapy.
- •severe comorbidities including lung disease, stroke, congestive heart failure of any severity, myocardial infarction, EKG abnormalities, uncontrolled hypertension - (sitting systolic BP <80 or > 160 mm Hg or diastolic BP > 100 mm Hg, unstable angina pectoris, hepatic or renal disease, insulin-dependent diabetes mellitus, history of cancer (other than in-situ cervical cancer or resected, cutaneous basal cell or squamous cell carcinoma), open cutaneous ulcers, known hepatitis B surface antigen (HbsAg) or hepatitis C virus (HCV) positive, or any other concurrent medical condition, which would make it unsafe for subjects to participate in the trial or interfere with the interpretation of the results.
- •Laboratories values which, at the time of the screening visit or at any time during the study that in the opinion of the Investigator would preclude participation in the study including: serum creatinine > 2.5 mg/dL, serum potassium < 3.5 mmol/L or > 5.5 mmol/L, serum aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase (ALP)> 3 times the upper limit of normal, platelet count < 100,000/mm3, WBC count < 3,000 cells/mm3, Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower limits of normal
- •Receipt of a live vaccine within 3 months of screening
- •participation in another investigational drug study within 90 days of screening.
- •known hypersensitivity to GM-CSF or any of its components
- •Known HIV-positive status or known history of any other immuno-suppressing disease.
- •Any mycobacterial disease.
- •Active severe infections within 4 weeks before screening visit, or between the screening and baseline visits.
- •Untreated Lyme disease.
- •History of TB or TB exposure, chronic hepatitis B or hepatitis C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy.
- •History of recent alcohol or substance abuse (< 1 year)
- •Pregnant or lactating females
- •History of non-compliance with other therapies
- •abnormal mental status sufficient to exclude informed consent
- •History of any opportunistic infection - to include but not limited to Pneumocystis carinii, aspergillosis, histoplasmosis, or atypical mycobacterium
- •History of Sickle cell disease.
Exclusion Criteria
- Not provided
Arms & Interventions
GM-CSF
Experimental
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (Drug)
Outcomes
Primary Outcomes
Safety of GM-CSF in patients with myasthenia gravis
Time Frame: 150 days
The number of subjects experiencing a Class II-V adverse event within 120 days of the start of treatment that is probably or definitely related to the study medication
The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 30 days post-treatment
Time Frame: 30 days
The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 60 days post-treatment
Time Frame: 60 days
The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 120 days post-treatment
Time Frame: 120 days
Secondary Outcomes
- Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at 60 days(60 days)
- Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 120(120 days)
- Change from baseline in the Myasthenia Gravis Composite score at day 60(60 days)
- Change from baseline in the Myasthenia Gravis Composite score at day 120(120 days)
- Change from baseline in Manual Muscle Testing (MMT) score at day 60(60 days)
- Change from baseline in Manual Muscle Testing (MMT) score at day 120(120 days)
- Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 60(60 days)
- Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 120(120 days)
- Change from baseline in Quality of Life Assessment (SF-36) at day 60(60 days)
- Change from baseline in Quality of Life Assessment (SF-36) at day 120(120 days)
- Change from baseline in acetylcholine receptor antibody titre level at day 60(60 days)
- Change from baseline in acetylcholine receptor antibody titre level at day 120(120 days)
- Change from baseline in prednisone dose at day 60(60 days)
- Change from baseline in prednisone dose at day 120 Days(120 days)
Investigators
Matthew N. Meriggioli, MD
Associate Professor
University of Illinois at Chicago
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal CancerRenal Cell CarcinomaNCT01176552Kidney Cancer Research Bureau35
Recruiting
Not Applicable
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary AtresiaGranulocyte Colony-stimulating FactorBiliary AtresiaNCT06708572National Liver Institute, Egypt40
Completed
Phase 2
Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid ArthritisArthritis, RheumatoidNCT02799472GlaxoSmithKline39
Unknown
Not Applicable
The Effect of the GM-CSF Gel on the Endometrial Thickness in Infertile Women With Thin EndometriumThin EndometriumNCT04100655Sir Run Run Shaw Hospital96
Unknown
Not Applicable
Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLFAcute on Chronic Liver FailureNCT01036932Govind Ballabh Pant Hospital50